Literature DB >> 11914183

Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault.

J T Arnold1, J T Isaacs.   

Abstract

The acquisition of an androgen-independent phenotype by prostate cancer cells is presently a death sentence for patients. In order to have a realistic chance of changing this outcome, an understanding of what drives the progression to androgen independence is critical. We review here a working hypothesis based on the position that the development of androgen-independent epithelial cells is the result of a series of cellular and molecular events within the whole tissue that culminates in the loss of normal tissue-maintained growth control. This tissue includes the epithelial and stromal cells, the supporting extracellular matrix and circulating hormones. This review discusses the characteristics of these malignant cells, the role of stromal cells involved in growth and the differentiation of epithelial cells, and the role of the extracellular matrix as a mediator of the phenotypes of stromal and epithelial cells. In addition, environmental, neuroendocrine and immune factors that may contribute to disturbance of the fine balance of the epithelial-stromal-extracellular matrix connection are considered. While the goal of many therapeutic approaches to prostate cancer has been androgen ablation or targeting the androgen receptor (AR) of epithelial cells, these therapies become ineffective as the cells progress beyond dependence on androgen for growth control. Twenty years ago Sir David Smithers debated that cancer is the result of loss of tolerance within tissues and the organizational failure of normal growth-control mechanisms. This is precipitated by prolonged or abnormal demands for regeneration or repair, rather than of any inherent disorder peculiar to each of the individual components involved. He wrote "It is not the cell itself that is disorderly, but its relationship with the rest of the tissue". We have gained significantly large amounts of precise data on the effects of androgenic ablation on cancerous prostate cells and on the role of the AR in prostate cancer. The need has come to compile this information towards a perspective of dysregulation of tissue as a whole, and to develop experimental systems to address this broader perspective to find and develop therapies for treatment and prevention.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11914183      PMCID: PMC4124629          DOI: 10.1677/erc.0.0090061

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  83 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.

Authors:  J Gao; J T Arnold; J T Isaacs
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

Review 3.  Hereditary prostate cancer: epidemiologic and clinical features.

Authors:  B S Carter; G S Bova; T H Beaty; G D Steinberg; B Childs; W B Isaacs; P C Walsh
Journal:  J Urol       Date:  1993-09       Impact factor: 7.450

Review 4.  The biology of hormone refractory prostate cancer. Why does it develop?

Authors:  J T Isaacs
Journal:  Urol Clin North Am       Date:  1999-05       Impact factor: 2.241

5.  Effect of normal endometrial stroma on growth and differentiation in Ishikawa endometrial adenocarcinoma cells.

Authors:  Julia T Arnold; Bruce A Lessey; Markku Seppälä; David G Kaufman
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.

Authors:  R A Lubet; G B Gordon; R A Prough; X D Lei; M You; Y Wang; C J Grubbs; V E Steele; G J Kelloff; C F Thomas; R D Moon
Journal:  Cancer Res       Date:  1998-03-01       Impact factor: 12.701

7.  2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.

Authors:  J E Green; M A Shibata; E Shibata; R C Moon; M R Anver; G Kelloff; R Lubet
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

8.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone.

Authors:  Z Culig; A Hobisch; M V Cronauer; A C Cato; A Hittmair; C Radmayr; J Eberle; G Bartsch; H Klocker
Journal:  Mol Endocrinol       Date:  1993-12

9.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.

Authors:  M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe
Journal:  N Engl J Med       Date:  1998-10-08       Impact factor: 91.245

10.  Intratissular androgens in benign prostatic hyperplasia and prostatic cancer.

Authors:  K D Voigt; W Bartsch
Journal:  J Steroid Biochem       Date:  1986-11       Impact factor: 4.292

View more
  62 in total

1.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Authors:  Hui Gao; Xuesong Ouyang; Whitney A Banach-Petrosky; William L Gerald; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

2.  Small carboxyl-terminal domain phosphatase 2 attenuates androgen-dependent transcription.

Authors:  James Thompson; Tatyana Lepikhova; Neus Teixido-Travesa; Maria A Whitehead; Jorma J Palvimo; Olli A Jänne
Journal:  EMBO J       Date:  2006-05-25       Impact factor: 11.598

3.  Exposure to ethinylestradiol during prenatal development and postnatal supplementation with testosterone causes morphophysiological alterations in the prostate of male and female adult gerbils.

Authors:  Ana Paula Silva Perez; Manoel Francisco Biancardi; Rejane Maira Góes; Fernanda Alcântara dos Santos; Sebastião Roberto Taboga
Journal:  Int J Exp Pathol       Date:  2011-02-12       Impact factor: 1.925

4.  Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8.

Authors:  Yohko Yamazaki; Tetsuya Someno; Masayuki Igarashi; Naoko Kinoshita; Masaki Hatano; Manabu Kawada; Isao Momose; Akio Nomoto
Journal:  J Antibiot (Tokyo)       Date:  2014-10-01       Impact factor: 2.649

5.  Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells.

Authors:  Sung-Lyul Lim; Sang-Yoon Park; Sukmin Kang; Dain Park; Sung-Hoon Kim; Jae-Young Um; Hyeung-Jin Jang; Jun-Hee Lee; Chul-Ho Jeong; Jung-Hee Jang; Kwang Seok Ahn; Seok-Geun Lee
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

6.  Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers.

Authors:  Markus Letsch; Andrew V Schally; Rebeca Busto; Ana M Bajo; Jozsef L Varga
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

Review 7.  Molecular mechanisms of castration-resistant prostate cancer progression.

Authors:  Smitha S Dutt; Allen C Gao
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

8.  Caveolae contribute to the apoptosis resistance induced by the alpha(1A)-adrenoceptor in androgen-independent prostate cancer cells.

Authors:  Maria Katsogiannou; Charbel El Boustany; Florian Gackiere; Philippe Delcourt; Anne Athias; Pascal Mariot; Etienne Dewailly; Nathalie Jouy; Christophe Lamaze; Gabriel Bidaux; Brigitte Mauroy; Natalia Prevarskaya; Christian Slomianny
Journal:  PLoS One       Date:  2009-09-18       Impact factor: 3.240

9.  Prostate cancer epigenetics: a review on gene regulation.

Authors:  Lena Diaw; Karen Woodson; John W Gillespie
Journal:  Gene Regul Syst Bio       Date:  2007-12-11

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.